domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md

@@ -25,6 +25,12 @@ This provides the strongest single empirical case for the claim that medical car
 
 ---
 
+### Additional Evidence (extend)
+*Source: [[2024-02-05-jama-network-open-digital-health-hypertension-disparities-meta-analysis]] | Added: 2026-03-31*
+
+Digital health interventions specifically tailored for disparity populations (racial/ethnic minorities, low-income, underinsured) achieved significant BP reductions at 12 months across 28 studies, demonstrating that technology CAN address behavioral/SDOH barriers when designed for the populations experiencing them—but generic deployment remains unproven.
+
+
 Relevant Notes:
 - [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
 - [[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]

domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md

@@ -24,6 +24,12 @@ The JACC study tracking 1999-2023 NHANES data reveals a striking failure mode in
 
 The population-level outcome of poor blood pressure control manifests as doubled hypertensive disease mortality 2000-2023, with 664,000 deaths in 2023 where hypertension was primary or contributing cause. Middle-aged adults (35-64) showed the most pronounced increases, indicating the treatment failure compounds over working-age years.
 
+### Additional Evidence (extend)
+*Source: [[2024-02-05-jama-network-open-digital-health-hypertension-disparities-meta-analysis]] | Added: 2026-03-31*
+
+Meta-analysis of 28 studies (8,257 patients) shows tailored digital health interventions achieve clinically significant BP reductions at 12 months in disparity populations, suggesting the binding constraint may be intervention design specificity rather than technology availability. Effect persists at 12 months, which is longer than typical digital health RCT effect decay.
+
+
 
 Relevant Notes:
 - [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]

domains/health/rpm-technology-stack-enables-facility-to-home-care-migration-through-ai-middleware-that-converts-continuous-data-into-clinical-utility.md

@@ -35,6 +35,12 @@ McKinsey identifies RPM as the fastest-growing home healthcare end-use segment a
 
 ---
 
+### Additional Evidence (confirm)
+*Source: [[2024-02-05-jama-network-open-digital-health-hypertension-disparities-meta-analysis]] | Added: 2026-03-31*
+
+Meta-analysis confirms that remote patient monitoring technology can deliver clinical utility (BP reduction) in disparity populations when properly implemented, validating the technical feasibility of the RPM stack. However, the 'tailored' qualifier suggests generic RPM deployment may not achieve the same outcomes.
+
+
 Relevant Notes:
 - [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]]
 - [[AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review]]

domains/health/tailored-digital-health-interventions-achieve-clinically-significant-bp-reductions-in-disparity-populations-but-effect-depends-on-design-specificity-not-generic-deployment.md

@@ -0,0 +1,28 @@
+---
+type: claim
+domain: health
+description: Meta-analysis of 28 studies shows digital health can reduce hypertension in disparity populations when interventions are specifically designed for them, but this does not demonstrate generic wearable/app deployment effectiveness
+confidence: experimental
+source: JAMA Network Open meta-analysis, 28 studies, 8,257 patients
+created: 2026-03-31
+attribution:
+  extractor:
+    - handle: "vida"
+  sourcer:
+    - handle: "jama-network-open"
+      context: "JAMA Network Open meta-analysis, 28 studies, 8,257 patients"
+---
+
+# Tailored digital health interventions achieve clinically significant systolic BP reductions at 12 months in US populations experiencing health disparities, but the effect is conditional on design specificity for these populations rather than generic deployment
+
+A systematic review and meta-analysis published in JAMA Network Open (February 2024) examined 28 studies with 8,257 patients across populations experiencing health disparities—racial/ethnic minorities, low-income adults, underinsured or uninsured individuals. The analysis found clinically significant reductions in systolic blood pressure at both 6 months and 12 months for digital health intervention recipients versus controls. Critically, the review characterizes these as 'tailored initiatives that leverage digital health' with 'potential to advance equity in hypertension outcomes.' The 12-month persistence is notable because most digital health RCTs show effect decay. However, the 28 studies represent tailored research programs with design specificity for disparity populations, not commercial product deployments. The gap between 'tailored intervention works in an RCT' and 'generic wearable deployment improves BP control at population scale' remains unbridged. This is conditional optimism: digital health CAN reach disparity populations, but only when designed for them, not through generic deployment of existing consumer products.
+
+---
+
+Relevant Notes:
+- [[only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint]]
+- [[hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure]]
+- [[rpm-technology-stack-enables-facility-to-home-care-migration-through-ai-middleware-that-converts-continuous-data-into-clinical-utility]]
+
+Topics:
+- [[_map]]

inbox/queue/2024-02-05-jama-network-open-digital-health-hypertension-disparities-meta-analysis.md

@@ -7,9 +7,14 @@ date: 2024-02-05
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
 priority: high
 tags: [hypertension, digital-health, health-disparities, blood-pressure, remote-patient-monitoring, equity, meta-analysis]
+processed_by: vida
+processed_date: 2026-03-31
+claims_extracted: ["tailored-digital-health-interventions-achieve-clinically-significant-bp-reductions-in-disparity-populations-but-effect-depends-on-design-specificity-not-generic-deployment.md"]
+enrichments_applied: ["only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md", "hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md", "rpm-technology-stack-enables-facility-to-home-care-migration-through-ai-middleware-that-converts-continuous-data-into-clinical-utility.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -57,3 +62,12 @@ PRIMARY CONNECTION: `only-23-percent-of-treated-us-hypertensives-achieve-blood-p
 WHY ARCHIVED: Provides conditional optimism that digital health can reach disparity populations — but the "tailored" qualifier is critical and unresolved by current commercial deployment scale
 
 EXTRACTION HINT: Extract as a claim with explicit scope: "tailored digital health interventions" (not generic wearable deployment). The tailoring qualifier prevents overgeneralization. Pair with the equity-widening source (PMC 2024) to create a divergence or a scoped claim set.
+
+
+## Key Facts
+- JAMA Network Open published systematic review February 5, 2024 (Volume 7, Issue 2, e2356070)
+- Meta-analysis included 28 studies with 8,257 patients total
+- Studies searched from inception to October 30, 2023 across Cochrane Library, Ovid Embase, Google Scholar, Ovid MEDLINE, PubMed, Scopus, and Web of Science
+- BP reductions were statistically significant at both 6 months and 12 months
+- Study populations: racial/ethnic minorities, low-income adults, underinsured or uninsured
+- Published before FDA TEMPO pilot and CMS ACCESS model announcements (December 2025)